Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiovascular and Renal Outcomes: A Systematic Review, Meta-analysis, and Meta-regression Analysis

Short title: Cardiovascular and renal efficacy of GLP-1RAs

Satoshi Yoshiji, MD^{1,2,3,4}, Hiroto Minamino, MD^{1,4}, Daisuke Tanaka, MD, PhD¹, Shunsuke Yamane MD, PhD¹, Norio Harada, MD, PhD¹, and Nobuya Inagaki, MD, PhD¹

¹Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan

²Department of Human Genetics, McGill University, Montréal, Québec, Canada

³Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

⁴Japan Society for the Promotion of Science, Tokyo, Japan

Correspondence

Nobuya Inagaki MD, PhD,

Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine,

Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

E-mail: inagaki@kuhp.kyoto-u.ac.jp

Tel: +81-075-751-3560

Fax: +81-075-751-4244

Abstract: 347 words.

Main text: 2981 words.

Number of Table: 1

Number of Figures: 4.

Supplementary material: 4 Tables and 5 Figures.

1 Abstract

2 **Background:** Cardiovascular and renal effects of glucagon-like peptide-1 receptor
3 agonists (GLP-1RAs) have been inconsistent in cardiovascular outcome trials, and
4 factors associated with the efficacy of GLP-1RAs remain to be clarified.

5 **Objective:** To evaluate cardiovascular and renal outcomes with GLP-1RAs and
6 associations between these outcomes and the magnitude of HbA1c or weight reduction.

7 **Data Sources and Study selection:** We searched PubMed/MEDLINE for randomized,
8 placebo-controlled trials of GLP-1RAs published until 11 August 2021 and selected
9 trials reporting major adverse cardiovascular events (MACE) as the primary outcome.

10 **Data Extraction and Synthesis:** We extracted data of 60,080 individuals from eight
11 studies (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, PIONEER 6,
12 REWIND, and AMPLITUDE-O) and conducted a meta-analysis with a random-effects
13 model to calculate pooled hazard ratios (HRs) of primary and secondary outcomes.
14 Furthermore, we performed a univariable meta-regression analysis of these outcomes
15 with HbA1c or weight reduction.

16 **Main outcomes and Measures:** The primary outcome was MACE (a composite of
17 cardiovascular mortality, nonfatal stroke, and nonfatal myocardial infarction).
18 Secondary outcomes included components of MACE, all-cause mortality,

19 hospitalization due to heart failure, and renal outcomes. Safety outcomes were severe

20 hypoglycemia, pancreatitis, pancreatic cancer, and retinopathy.

21 **Results:** GLP-1RAs reduced MACE (HR 0.86; 95% CI 0.80, 0.93; $P < 0.001$) and

22 secondary outcomes including cardiovascular mortality (0.87; 0.80 0.94; $P = 0.001$),

23 nonfatal myocardial infarction (0.90; 0.83, 0.98; $P = 0.020$) nonfatal stroke (0.83; 0.76,

24 0.92; $P < 0.001$), and the composite renal outcome (0.80; 0.73, 0.87; $P < 0.001$). No

25 increase in the incidence of safety outcomes was observed with GLP-1RAs.

26 Meta-regression analysis showed that HbA1c reduction was associated with logarithm

27 of HR (log-HR) of MACE ($P = 0.045$; $R^2 = 0.64$) and the composite renal outcome ($P =$

28 0.045 ; $R^2 = 0.80$), whereas weight reduction was not associated with any outcome.

29 Every 1.0% HbA1c reduction was associated with a decrease in log-HR of MACE and

30 the composite renal outcome by 0.27 and 0.35, respectively.

31 **Conclusions:** GLP-1RAs showed favorable effects on cardiovascular and renal

32 outcomes. Furthermore, reduction in HbA1c, but not body weight, was associated with

33 cardiovascular and renal risk reduction during the treatment with GLP-1RAs.

34

35

36 **Introduction**

37 Major adverse cardiovascular events (MACE) and chronic kidney disease are leading
 38 causes of morbidity and mortality in individuals with type 2 diabetes. Prevention and
 39 management of these disorders play pivotal roles in the treatment of type 2 diabetes^{1,2}.
 40 To date, a series of randomized, placebo-controlled clinical trials on cardiovascular and
 41 renal outcomes with glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been
 42 reported, including ELIXA, LEADER, SUSTAIN-6, HARMONY, PIONEER 6,
 43 REWIND, and AMPLITUDE-O³⁻¹⁰. These trials evaluated the safety and efficacy of
 44 GLP-1RAs on the primary composite MACE outcome (cardiovascular mortality,
 45 nonfatal stroke, or nonfatal myocardial infarction) as well as secondary outcomes,
 46 including individual components of MACE, hospitalization due to heart failure,
 47 all-cause mortality, and renal outcomes. In these trials, GLP-1RAs consistently showed
 48 cardiovascular and renal safety, but cardiovascular and renal efficacy were inconsistent
 49 across trials: LEADER, SUSTAIN-6, and REWIND reduced MACE compared to
 50 placebo, whereas ELIXA and EXSCEL did not reduce MACE. Notably,
 51 AMPLITUDE-O reduced MACE for the first time as a trial with an exendin-based
 52 GLP-1RA¹⁰.

53 Regarding the mechanism of action for cardiovascular and renal efficacy, it has

54 been reported that reducing HbA1c or body weight contributes to cardiovascular, renal,
55 and mortality risk reduction¹¹⁻¹⁶. However, although cardiovascular outcome trials of
56 GLP-1RAs reported effective reductions in HbA1c and body weight, it is still unclear
57 whether HbA1c or body weight reduction is associated with the cardioprotective and
58 renoprotective profile.

59 To examine overall cardiovascular and renal effects as well as safety profiles of
60 GLP-1RAs, we performed a systematic review and meta-analysis of cardiovascular
61 outcome trials of GLP-1RAs, including AMPLITUDE-O. Furthermore, to evaluate
62 whether the magnitude of HbA1c or body weight reduction is associated with
63 cardiovascular and renal outcomes, we conducted a univariable meta-regression
64 analysis of cardiovascular and renal outcomes with HbA1c or weight reduction.

65

66 **Methods**

67 **Data Sources and Searches**

68 We performed a data search in accordance with the Preferred Reporting Items for
69 Systematic Reviews and Meta-Analysis (PRISMA) statement¹⁷. We searched the
70 PubMed/MEDLINE database for eligible randomized, placebo-controlled trials of
71 GLP-1RAs on MACE in individuals with type 2 diabetes, published until 11 August

2021. We placed no restrictions on the study population or language. The search terms were described in Supplementary Figure 1. The protocol for this study is registered in PROSPERO (CRD42021273058).

Study Selection

We selected studies reporting MACE as the primary outcome. For selected trials, we also evaluated secondary outcomes and safety outcomes. SY and HM independently conducted the search and solved any discordance through discussion.

We selected randomized, placebo-controlled trials of GLP-1RAs reporting major adverse cardiovascular events (MACE) as the primary outcome. We excluded studies not reporting MACE or a design of interest.

Data Extraction and Quality Assessment

We extracted summary statistics of the eligible studies from published articles of the trials and their supplementary materials. We did not seek individual-level data. For primary and secondary outcomes, we obtained relevant hazard ratios (HRs) and 95% confidence intervals (95% CIs). For safety outcomes, odds ratios (ORs) and 95% CIs were obtained. We evaluated the risk of bias for eligible studies with the Cochrane Risk

of Bias Tool¹⁸. SY and HM conducted the data extraction and quality assessment.

Data Synthesis and Analysis

For the present meta-analysis, the primary outcome was the HR of MACE. The secondary outcomes were the HRs of individual components of MACE, all-cause mortality, hospitalization due to heart failure, composite renal outcome, and renal function outcome. Definitions of the composite renal outcome and the renal function outcome were not standardized across the trials; detailed definitions of these renal outcomes for each trial are provided in Supplementary Table 1. Definitions of the safety outcomes, including severe hypoglycemia, pancreatitis, pancreatic cancer, and retinopathy, are also described in Supplementary Table 2.

For the meta-analysis, we used the inverse variance method with a random-effects model to obtain a weighted average of HRs or ORs with 95% CIs. We used the DerSimonian-Laird estimator for the assessment of between-study variance¹⁹. We used the I^2 index and Cochran's Q test to measure the degree of heterogeneity. The degree of heterogeneity based on the I^2 index was defined as low (I^2 index $\leq 25\%$), moderate (I^2 index 26–50%), and high (I^2 index $> 50\%$)²⁰. P values of < 0.05 for Cochran's Q test represent significant heterogeneity between the studies.

Regarding meta-regression analysis, normalized HbA1c and body weight reduction of each GLP-1RA were calculated from head-to-head clinical as described previously²¹. We defined HbA1c reduction and body weight reduction of liraglutide as 1.0% and 1.0 kg, respectively, and normalized those of other GLP-1RAs against liraglutide. We delineated liraglutide as a normalizer because liraglutide was compared head-to-head against all the other GLP-1RAs²²⁻²⁸. Using either normalized HbA1c change or body weight change as an independent variable, we conducted univariable meta-regression analyses for cardiovascular and renal outcomes with the log-HR as a dependent variable. *P* values of < 0.05 represented significance.

We performed all statistical analysis with R (version 4.0.2, R Foundation for Statistical Computing, Vienna, Austria) and the R package “meta” version 4.18.2.

Results

Study identification

Among 212 articles screened with the prespecified screening strategy, eight randomized, placebo-controlled cardiovascular outcome trials which defined MACE as the primary outcome were identified. Data from the following eight trials with a total of 60,080 individuals were analyzed in the present meta-analysis: ELIXA, LEADER, SUSTAIN-6,

EXSCEL, HARMONY, PIONEER 6, REWIND, and AMPLITUDE-O (Table 1). The study selection process based on PRISMA is presented in Supplementary Figure 1. According to the Cochrane risk of bias tool¹⁸, the risk of bias for all included trials was evaluated as low (Supplementary Table 3).

ELIXA, EXSCEL, and AMPLITUDE-O evaluated GLP-1RAs with an exendin-based structural backbone, whereas LEADER, SUSTAIN-6, HARMONY, and PIONEER 6 examined those with a human GLP-1 backbone. For all trials other than ELIXA, the primary outcome was MACE, which was the time to the first occurrence of cardiovascular mortality, nonfatal stroke, or nonfatal myocardial infarction. For ELIXA, the primary outcome was extended MACE, which was MACE with an additional component, i.e., hospitalization due to unstable angina. However, hospitalization due to unstable angina accounted for less than 2.5% of the primary outcome in ELIXA. Given that hospitalization for unstable angina had minimal influence on the primary outcome, we included ELIXA in the meta-analysis. HARMONY and PIONEER 6 did not report renal outcomes and were excluded from the analysis for renal outcomes.

141

142 **Baseline characteristics**

143 The baseline characteristics of the eight trials are summarized in Table 1. The median

144 duration of follow-up was the shortest in PIONEER 6 (1.3 years) and the longest in
145 REWIND (5.4 years). The average age ranged from 59.9 years in ELIXA to 66.2 years
146 in REWIND. Of the 60,080 individuals, 21930 (37%) were women, and 45640 (76%)
147 were of white ethnicity. Average body mass index varied from 30.1 kg/m² (ELIXA) to
148 32.8 kg/m² (SUSTAIN-6), and average baseline HbA1c ranged from 7.3% (REWIND)
149 to 8.9% (AMPLITUDE-O), and average estimated glomerular filtration rate (eGFR)
150 from 74 mL/min per 1.73 m² (PIONEER 6) to 80 mL/min per 1.73 m² (LEADER and
151 SUSTAIN-6). The proportion of individuals with previously established cardiovascular
152 disease was 77% (46,105 out of 60,080 individuals) across the eight trials and ranged
153 from 31% (REWIND) to 100% (ELIXA and HARMONY).

154

155 **Meta-analysis**

156 Overall, GLP-1RAs reduced MACE (HR 0.86; 95% CI 0.80, 0.93; $P < 0.001$) with
157 moderate heterogeneity ($I^2 = 44.5\%$, $P = 0.082$) (Figure 1). As for the individual
158 components of MACE, GLP-1RAs reduced cardiovascular mortality (HR 0.87; 95% CI
159 0.80, 0.94; $P = 0.001$) with low heterogeneity ($I^2 = 12.8\%$, $P = 0.330$), nonfatal
160 myocardial infarction (HR 0.90; 95% CI 0.83, 0.98; $P = 0.020$) with moderate
161 heterogeneity ($I^2 = 27.4\%$, $P = 0.210$), and nonfatal stroke (HR 0.83; 95% CI 0.76, 0.92;

162 $P < 0.001$) with low heterogeneity ($I^2 = 0\%$, $P = 0.639$). Normalized HbA1c and body
163 weight reduction used in the meta-regression analysis were presented in Supplementary
164 Table 4.

165 As for other secondary outcomes (Figure 2), GLP-1RAs reduced all-cause
166 mortality (HR 0.88; 95% CI 0.82, 0.94; $P < 0.001$) with low heterogeneity ($I^2 = 10.5\%$,
167 $P = 0.349$), hospitalization due to heart failure (HR 0.89; 95% CI 0.82, 0.98; $P = 0.013$)
168 with low heterogeneity ($I^2 = 2.5\%$, $P = 0.410$), composite renal outcome (HR 0.80; 95%
169 CI 0.73, 0.87; $P < 0.001$) with moderate heterogeneity ($I^2 = 45.0\%$, $P = 0.106$), and
170 renal function outcome (HR 0.84; 95% CI 0.73, 0.97; $P = 0.016$) with moderate
171 heterogeneity ($I^2 = 31.4\%$, $P = 0.200$).

172

173 **Subgroup analysis**

174 In a subgroup analysis of MACE stratified by the prior history of established
175 cardiovascular disease (Supplementary Figure 2), GLP-1RAs reduced MACE in
176 individuals with established cardiovascular disease (HR 0.85; 95% CI 0.79, 0.92; $P <$
177 0.001) with moderate heterogeneity ($I^2 = 48.0\%$, $P = 0.060$), but not in those without
178 established cardiovascular disease (HR 0.94; 95% CI 0.83, 1.06; $P = 0.303$) with
179 moderate heterogeneity ($I^2 = 0.0\%$, $P = 0.514$).

180 In another subgroup analysis of MACE stratified by the structural backbones of
181 GLP-1RAs (Supplementary Figure 3), exendin-based GLP-1RAs did not reduce MACE
182 (HR 0.90; 95% CI 0.78, 1.04; $P = 0.163$) and had a high and significant heterogeneity
183 among studies ($I^2 = 67.2\%$, $P = 0.047$). On the other hand, human GLP-1-based
184 GLP-1RAs reduced MACE (HR 0.84; 95% CI 0.79, 0.90; $P < 0.001$) with low
185 heterogeneity ($I^2 = 0.0\%$, $P = 0.513$).

186

187 **Safety outcomes**

188 Regarding safety outcomes (Supplementary Figure 4), GLP-1RAs did not increase ORs
189 for severe hypoglycemia (OR 0.87; 95% CI 0.71, 1.08; $P = 0.208$), pancreatitis (OR
190 1.16; 95% CI 0.90, 1.60; $P = 0.384$), pancreatic cancer (OR 0.97; 95% CI 0.64, 1.48; P
191 $= 0.892$), or retinopathy (OR 1.07; 95% CI 0.92, 1.25; $P = 0.400$).

192

193 **Meta-regression analysis**

194 The meta-regression analysis of the eight pooled trials showed that normalized HbA1c
195 reduction was associated with the log-HR of MACE (slope -0.27; 95% CI -0.53, -0.01;
196 $P = 0.045$; $R^2 = 0.64$), whereas normalized body weight reduction had no association
197 with the log-HR of MACE (slope = -0.05; 95% CI -0.17, 0.07; $P = 0.390$; $R^2 < 0.01$)

(Figure 3). Among secondary outcomes, normalized HbA1c reduction was associated with the log-HR of the composite renal outcome (slope = -0.35; 95% CI -0.69, -0.01; $P = 0.045$; $R^2 = 0.80$) (Figure 4). Although the associations between normalized HbA1c reduction and other secondary outcomes were not significant, all outcomes except hospitalization due to heart failure showed negative slopes for the regression line, which was directionally concordant with MACE. As for body weight, normalized body weight reduction was not associated with any secondary outcome; the 95% CIs were wide and ranged from negative to positive values (Figure 4 and Supplementary Figure 5).

Discussion

Systematic review and meta-analysis

The present meta-analysis and meta-regression analysis included a total of 60,080 individuals from eight trials of GLP-1RAs, including AMPLITUDE-O. Overall, GLP-1RAs reduced MACE, its components, cardiovascular mortality, nonfatal myocardial infarction, nonfatal stroke, all-cause mortality, hospitalization due to heart failure, composite renal outcome, renal function outcome. Regarding safety outcomes, the occurrence of severe hypoglycemia, pancreatitis, pancreatic cancer, or retinopathy was not increased with GLP-1RAs.

216 In a subgroup analysis stratified by a prior history of established cardiovascular
217 disease (Supplementary Figure 2), GLP-1RAs reduced MACE in individuals with
218 established cardiovascular disease but not in those without established cardiovascular
219 disease. Taking into account the anti-atherosclerotic properties of GLP-1RAs²⁹, it is
220 conceivable that cardiovascular benefits of GLP-1RAs were more prominent in
221 individuals with established cardiovascular disease. Our findings support current
222 guidelines which recommend GLP-1RAs for the treatment of diabetes in individuals
223 with established cardiovascular diseases or in those who are at high risk of
224 cardiovascular diseases^{2, 30, 31}.

225 In terms of individual study details, all the studies, except for ELIXA and
226 EXSCEL, reported a reduction in MACE. Notably, in AMPLITUDE-O, efpeglenatide
227 reduced MACE for the first time as an exendin-based GLP-1RA. Given the findings
228 from AMPLITUDE-O, we conducted the subgroup analysis of MACE according to the
229 structural backbone of GLP-1RAs (Supplementary Figure 3). Whereas human
230 GLP-1-based GLP-1RAs reduced MACE (HR 0.84; 95% CI 0.79, 0.90; $P < 0.001$) with
231 low heterogeneity ($I^2 = 0.0\%$, $P = 0.513$), exendin-based GLP-1RAs did not reduce
232 MACE (HR 0.90; 95% CI 0.78, 1.04; $P = 0.163$). The difference could be due to the
233 large heterogeneity of exendin-based GLP-1 trials ($I^2 = 67.2\%$, $P = 0.047$). Individually,

234 ELIXA was different from the other two trials (EXSCEL and AMPMLITUDE-O) in the
235 sense that it recruited individuals with a recent acute coronary syndrome³. It should also
236 be noted that EXSCEL reported poor adherence to the drug (around 40% of premature
237 discontinuation of the trial) and that lixisenatide, used in ELIXA, has the shortest
238 half-life of 2–4 hours, which is markedly shorter than that of other GLP-1RAs³².
239 Therefore, in ELIXA and EXSCEL, multiple factors such as study design, adherence to
240 the drug, and half-life could have influenced the cardiovascular outcomes. On the other
241 hand, AMPLITUDE-O achieved a reduction of MACE and other secondary outcomes
242 despite the shortest follow-up periods of 1.8 years (2.1 years for ELIXA and 3.2 years
243 for EXSCEL)^{3, 6, 10}, showing that exendin-based GLP-1RAs can also exert
244 cardioprotective and renoprotective effects.

245 In terms of safety outcomes of GLP-1RAs (Supplementary Figure 4), our
246 meta-analysis showed that the occurrence of severe hypoglycemia, pancreatitis,
247 pancreatic cancer, or retinopathy did not increase, although definitions of safety
248 outcomes were not standardized across trials (Supplementary Table 2). Individually, the
249 incidence of retinopathy was increased in SUSTAIN-6, which may be attributable to the
250 rapid lowering of blood glucose³³. Currently, a trial on the long-term effects of
251 semaglutide on diabetic retinopathy (FOCUS; ClinicalTrials.gov NCT03811561)³⁴ is

252 underway, which is expected to be completed in 2024.

253

254 **Meta-regression analysis**

255 Regarding the underlying mechanism of GLP-1RA efficacy, factors associated with the
256 cardioprotective and renoprotective profiles of GLP-1RAs remain unclear²⁹. Therefore,
257 to evaluate whether reduction in HbA1c or body weight (two key clinical variables
258 decreased by GLP-1RAs) is associated with the cardioprotective and renoprotective
259 effects of GLP-1RAs, we conducted a meta-regression analysis of the log-HR of MACE
260 and other secondary outcomes with normalized reduction of HbA1c or body weight.

261 As for the primary composite MACE outcome (Figure 4), the results showed
262 that the log-HR of MACE decreased by 0.27 for every 1.0% normalized HbA1c
263 reduction. In contrast, log-HR of MACE was not associated with normalized body
264 weight reduction. In individual studies, albiglutide caused minimal weight reduction but
265 still showed a reduction in log-HR of MACE. On the other hand, lixisenatide, which
266 showed greater normalized body weight reduction than albiglutide and dulaglutide, did
267 not reduce cardiovascular risk.

268 The present findings that only HbA1c reduction but not body weight reduction
269 is associated with cardiovascular risk were consistent with a recent post-hoc mediation

study of the LEADER trial³⁵. The mediation analysis showed that HbA1c was potentially the largest mediator of cardiovascular efficacy of liraglutide, with percentage mediation being 41–83%, whereas body weight was calculated to have a much smaller percentage mediation of 4–14%. Considering findings from our meta-regression analysis and the mediation analysis, it seems likely that HbA1c reduction can be a marker of cardiovascular efficacy of GLP-1RAs. However, whether HbA1c reduction constitutes a direct contributor or represents unmeasured contributors remains to be clarified. From a different standpoint, previous intervention trials, including DCCT/EDIC^{11, 12} and UKPDS¹³⁻¹⁵, which evaluated the safety and efficacy of intensive glucose-lowering therapies, also supported the association of HbA1c lowering with cardiovascular risk reduction. However, these studies required more than ten years of follow-up to detect cardiovascular risk reduction, which is far longer than those of the trials in the present analysis. These discrepancies indicate that not only HbA1c lowering but pleiotropic effects of GLP-1RAs beyond glucose-lowering, such as amelioration of endothelial damage and chronic inflammation^{36, 37}, may contribute to cardiovascular risk reduction.

As for secondary outcomes, normalized HbA1c reduction was also associated with the composite renal outcome. On the other hand, normalized body weight

288 reduction had high variability among studies and was not associated with any secondary
289 outcome (Figure 4 and Supplementary Figure 5). Consistent with our findings that
290 reduction in HbA1c but not body weight is associated with the composite renal outcome,
291 another mediation analysis of LEADER and SUSTAIN 6 trials on the composite renal
292 outcome suggested that HbA1c is potentially the greatest mediator of renal benefits,
293 whereas body weight has little to no effect³⁸. In contrast to the association of HbA1c
294 reduction with the renal composite outcome, we did not find a significant association
295 with the renal function outcome (the narrower renal endpoint). This discrepancy may be
296 explained by the definitions of these outcomes: the renal composite outcome included
297 new-onset macroalbuminuria, which is predominantly prevented by GLP-1RAs³⁹,
298 whereas renal function outcome did not (Supplementary Table 1). However, we must
299 note that cardiovascular outcome trials were not designed to detect renal events as the
300 primary outcome. In this regard, FLOW trial (NCT03819153)⁴⁰, which evaluates the
301 effects of semaglutide on hard renal endpoints as the primary outcome in individuals
302 with chronic kidney disease, is expected to provide more insights into the renal effects
303 of the GLP-1RAs.

304

305 **Limitations**

306 This study has several limitations. First, we used only summary data for
307 meta-analysis and did not use individual-level data. Second, although heterogeneity
308 between studies was generally low–moderate, some differences between the trials
309 generated notable heterogeneity. For example, the unique recruiting criteria of ELIXA
310 (all individuals had a recent history of acute coronary syndrome)³ likely contributed to
311 high heterogeneity among studies with exendin-based GLP-1RAs. Third, although we
312 conducted the meta-analysis and meta-regression analysis on various secondary
313 outcomes in addition to the primary outcome, the included trials were not sufficiently
314 powered to detect the differences in the secondary outcomes. This may have reduced
315 the statistical power for meta-regression analysis of the secondary outcomes.

316

317 **Conclusions**

318 In conclusion, the present systematic review and meta-analysis showed that GLP-1RAs
319 reduce MACE, its components, all-cause mortality, hospitalization due to heart failure,
320 the composite renal outcome, and the renal function outcome. Furthermore, the
321 meta-regression analysis showed that reduction in HbA1c, but not body weight, is
322 associated with cardiovascular and renal risk reduction during the treatment with
323 GLP-1RAs.

325 Data sharing

326 All the data were extracted from publicly available sources and included in the present
327 article.

328

329 Acknowledgements

330 SY and HM are supported by the Japan Society for the Promotion of the Science.

331

332 Author contributions

333 SY designed the study and analyzed the data. SY and HM collected and interpreted the
334 data and wrote the first draft of the manuscript. HM and DT verified the analysis. DT,
335 SYM, NH, and NI contributed to data interpretation and critical review of the
336 manuscript. NI is the guarantor of the study.

337

338 Funding

339 None.

340

341 Conflict of interests

342 NI received research funds from Terumo Corp., Drawbridge, Inc., and asken Inc. NI
343 received speaker honoraria from Kowa Co., Ltd., MSD K.K, Astellas Pharma Inc.,
344 Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Nippon Boehringer
345 Ingelheim Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp.,
346 Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., Eli Lilly Japan K.K.; received
347 scholarship grant from Kissei Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi-Sankyo
348 Co., Ltd., Mitsubishi Tanabe Pharma Corp., Takeda Pharmaceutical Co., Ltd., Japan
349 Tobacco Inc., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Astellas
350 Pharma Inc., MSD K.K., Ono Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co.,
351 Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Novartis
352 Pharma K.K., Life Scan Japan K.K. NI is an advisory board member of Novo Nordisk.
353 NI and NH were investigators for SUSTAIN and PIONEER programs. SY, HM, DT,
354 and SYM declare no conflict of interests.

355 **References**

- 356 1. American Diabetes Association. Cardiovascular disease and risk management:
357 standards of medical care in diabetes—2021. *Diabetes Care*. 2021;44:S125-S150.
- 358 2. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of
359 hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes
360 Association (ADA) and the European Association for the Study of Diabetes (EASD).
361 *Diabetes Care*. 2020;43:487-493.
- 362 3. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2
363 diabetes and acute coronary syndrome. *New Engl J Med*. 2015;373:2247-2257.
- 364 4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and
365 cardiovascular outcomes in type 2 diabetes. *New Engl J Med*. 2016;375:311-322.
- 366 5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes
367 in patients with type 2 diabetes. *New Engl J Med*. 2016;375:1834-1844.
- 368 6. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on
369 cardiovascular outcomes in type 2 diabetes. *New Engl J Med*. 2017;377:1228-1239.
- 370 7. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular
371 outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony
372 Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*.
373 2018;392:1519-1529.

- 374 8. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and
375 cardiovascular outcomes in patients with type 2 diabetes. *New Engl J Med*.
376 2019;381:841-851.
- 377 9. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular
378 outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled
379 trial. *Lancet*. 2019;394:121-130.
- 380 10. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes
381 with efpeglenatide in type 2 diabetes. *New Engl J Med*. 2021;385:896-907.
- 382 11. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of
383 diabetes on the development and progression of long-term complications in
384 insulin-dependent diabetes mellitus. *New Engl J Med*. 1993;329:977-986.
- 385 12. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and
386 cardiovascular disease in patients with type 1 diabetes. *New Engl J Med*.
387 2005;353:2643-2653.
- 388 13. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin
389 compared with conventional treatment and risk of complications in patients with type 2
390 diabetes (UKPDS 33). *Lancet*. 1998;352:837-853.
- 391 14. UKPDS Group. Effect of intensive blood-glucose control with metformin on

- 392 complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;
393 352:854-865.
- 394 15. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose
395 control in type 2 diabetes. *New Engl J Med*. 2008;359:1577-1589.
- 396 16. Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for
397 adults who are obese on mortality, cardiovascular disease, and cancer: systematic
398 review and meta-analysis. *BMJ*. 2017;359:j4849.
- 399 17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an
400 updated guideline for reporting systematic reviews. *BMJ*. 2021;327:n71.
- 401 18. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's
402 tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928-d.
- 403 19. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemp*
404 *Clin Trials* .2015;45:139-145.
- 405 20. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing
406 heterogeneity in meta-analysis: Q statistic or I^2 index? *Psychol Methods*.
407 2006;11:193-206.
- 408 21. Taylor SI. GLP-1 receptor agonists: differentiation within the class. *Lancet*
409 *Diabetes Endocrinol*. 2018;6:83-85.

- 410 22. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide
411 once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label
412 study. *Lancet*. 2013;381:117-124.
- 413 23. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus
414 once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a
415 randomised, open-label, phase 3, non-inferiority trial. *Lancet*. 2014;384:1349-1357.
- 416 24. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus
417 once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral
418 drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3
419 study. *Lancet Diabetes Endocrinol*. 2014;2:289-297.
- 420 25. Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B.
421 Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: A
422 26-week randomized controlled clinical trial. *Diabetes Care*. 2016;39:1501-1509.
- 423 26. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous
424 liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind,
425 phase 3a trial. *Lancet*. 2019;394:39-50.
- 426 27. Rosenstock J, Sorli CH, Trautmann ME, et al. Once-weekly efpeglenatide
427 dose-range effects on glycemic control and body weight in patients with type 2 diabetes

- 428 on metformin or drug naive, referenced to liraglutide. *Diabetes Care*.
- 429 2019;42:1733-1741.
- 430 28. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of
- 431 once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral
- 432 antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). *Diabetes Metab*.
- 433 2020; 46:100-109.
- 434 29. Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1
- 435 receptor agonist cardiovascular outcomes trials. *Trends Endocrinol Metab*.
- 436 2019;30:578-589.
- 437 30. Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision
- 438 pathway on novel therapies for cardiovascular risk reduction in patients with type 2
- 439 Diabetes. *J Am Coll Cardiol*. 2020;76:1117-1145.
- 440 31. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes,
- 441 pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
- 442 *Eur Heart J*. 2020;41:255-323.
- 443 32. Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1
- 444 agonists: current advancements & challenges. *Biomed Pharmacother*.
- 445 2018;108:952-962.

- 446 33. Sharma A, Parachuri N, Kumar N, et al. Semaglutide and the risk of diabetic
447 retinopathy—current perspective. *Eye*. 2021; Published online 9 August.
448 <https://doi.org/10.1038/s41433-021-01741-5>.
- 449 34. Novo Nordisk. A research study to look at how semaglutide compared to
450 placebo affects diabetic eye disease in people with type 2 diabetes. Identifier:
451 NCT03811561. <https://clinicaltrials.gov/ct2/show/NCT03811561>. Accessed 11 August
452 2021.
- 453 35. Buse JB, Bain SC, Mann JFE, et al. Cardiovascular risk reduction with
454 liraglutide: An exploratory mediation analysis of the LEADER Trial. *Diabetes Care*.
455 2020;43:1546-1552.
- 456 36. Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1
457 and analogs on cell signaling, metabolism, and function. *Front Endocrinol (Lausanne)*.
458 2018; 9: 672.
- 459 37. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. *Cell Metab*.
460 2016;24:15-30.
- 461 38. Mann JFE, Buse JB, Idorn T, et al. Potential kidney protection with liraglutide
462 and semaglutide: Exploratory mediation analysis. *Diab Obes Metab*.
463 2021;23:2058-2066.

- 464 39. Vitale M, Haxhi J, Cirrito T, Pugliese G. Renal protection with glucagon-like
465 peptide-1 receptor agonists. *Curr Opin Pharmacol.* 2020;54:91-101. 1.
466 American Diabetes Association. Cardiovascular disease and risk management:
467 standards of medical care in diabetes—2021. *Diabetes Care.* 2021;44:S125-S150.
- 468 2. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of
469 hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes
470 Association (ADA) and the European Association for the Study of Diabetes (EASD).
471 *Diabetes Care.* 2020;43:487-493.
- 472 3. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2
473 diabetes and acute coronary syndrome. *New Engl J Med.* 2015;373:2247-2257.
- 474 4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and
475 cardiovascular outcomes in type 2 diabetes. *New Engl J Med.* 2016;375:311-322.
- 476 5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes
477 in patients with type 2 diabetes. *New Engl J Med.* 2016;375:1834-1844.
- 478 6. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on
479 cardiovascular outcomes in type 2 diabetes. *New Engl J Med.* 2017;377:1228-1239.
- 480 7. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular
481 outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony

482 Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*.

483 2018;392:1519-1529.

484 8. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and

485 cardiovascular outcomes in patients with type 2 diabetes. *New Engl J Med*.

486 2019;381:841-851.

487 9. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular

488 outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled

489 trial. *Lancet*. 2019;394:121-130.

490 10. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes

491 with efpeglenatide in type 2 diabetes. *New Engl J Med*. 2021;385:896-907.

492 11. Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of

493 diabetes on the development and progression of long-term complications in

494 insulin-dependent diabetes mellitus. *New Engl J Med*. 1993;329:977-986.

495 12. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and

496 cardiovascular disease in patients with type 1 diabetes. *New Engl J Med*.

497 2005;353:2643-2653.

498 13. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin

499 compared with conventional treatment and risk of complications in patients with type 2

- 500 diabetes (UKPDS 33). *Lancet*. 1998;352:837-853.
- 501 14. UKPDS Group. Effect of intensive blood-glucose control with metformin on
502 complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*. 1998;
503 352:854-865.
- 504 15. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose
505 control in type 2 diabetes. *New Engl J Med*. 2008;359:1577-1589.
- 506 16. Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for
507 adults who are obese on mortality, cardiovascular disease, and cancer: systematic
508 review and meta-analysis. *BMJ*. 2017;359:j4849.
- 509 17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an
510 updated guideline for reporting systematic reviews. *BMJ*. 2021;327:n71.
- 511 18. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's
512 tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928-d.
- 513 19. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. *Contemp*
514 *Clin Trials* .2015;45:139-145.
- 515 20. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing
516 heterogeneity in meta-analysis: Q statistic or I^2 index? *Psychol Methods*.
517 2006;11:193-206.

- 518 21. Taylor SI. GLP-1 receptor agonists: differentiation within the class. *Lancet*
519 *Diabetes Endocrinol.* 2018;6:83-85.
- 520 22. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide
521 once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label
522 study. *Lancet.* 2013;381:117-124.
- 523 23. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus
524 once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a
525 randomised, open-label, phase 3, non-inferiority trial. *Lancet.* 2014;384:1349-1357.
- 526 24. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus
527 once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral
528 drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3
529 study. *Lancet Diabetes Endocrinol.* 2014;2:289-297.
- 530 25. Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B.
531 Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: A
532 26-week randomized controlled clinical trial. *Diabetes Care.* 2016;39:1501-1509.
- 533 26. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous
534 liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind,
535 phase 3a trial. *Lancet.* 2019;394:39-50.

- 536 27. Rosenstock J, Sorli CH, Trautmann ME, et al. Once-weekly efpeglenatide
537 dose-range effects on glycemic control and body weight in patients with type 2 diabetes
538 on metformin or drug naive, referenced to liraglutide. *Diabetes Care*.
539 2019;42:1733-1741.
- 540 28. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of
541 once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral
542 antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). *Diabetes Metab*.
543 2020; 46:100-109.
- 544 29. Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1
545 receptor agonist cardiovascular outcomes trials. *Trends Endocrinol Metab*.
546 2019;30:578-589.
- 547 30. Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision
548 pathway on novel therapies for cardiovascular risk reduction in patients with type 2
549 Diabetes. *J Am Coll Cardiol*. 2020;76:1117-1145.
- 550 31. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes,
551 pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
552 *Eur Heart J*. 2020;41:255-323.
- 553 32. Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1

- agonists: current advancements & challenges. *Biomed Pharmacother.* 2018;108:952-962.
33. Sharma A, Parachuri N, Kumar N, et al. Semaglutide and the risk of diabetic retinopathy—current perspective. *Eye.* 2021; Published online 9 August. <https://doi.org/10.1038/s41433-021-01741-5>.
34. Novo Nordisk. A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes. Identifier: NCT03811561. <https://clinicaltrials.gov/ct2/show/NCT03811561>. Accessed 11 August 2021.
35. Buse JB, Bain SC, Mann JFE, et al. Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the LEADER Trial. *Diabetes Care.* 2020;43:1546-1552.
36. Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. *Front Endocrinol (Lausanne).* 2018; 9: 672.
37. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. *Cell Metab.* 2016;24:15-30.
38. Mann JFE, Buse JB, Idorn T, et al. Potential kidney protection with liraglutide

572 and semaglutide: Exploratory mediation analysis. *Diab Obes Metab.*

573 2021;23:2058-2066.

574 39. Vitale M, Haxhi J, Cirrito T, Pugliese G. Renal protection with glucagon-like

575 peptide-1 receptor agonists. *Curr Opin Pharmacol.* 2020;54:91-101.

576 40. Novo Nordisk. A Research study to see how semaglutide works compared to

577 placebo in people with type 2 diabetes and chronic kidney disease. Identifier:

578 NCT03819153. <https://clinicaltrials.gov/ct2/show/NCT03819153>. Accessed 11 August

579 2021.

580 Figure legends

581

582 **Figure 1.** Effects of GLP-1RAs on the primary composite MACE outcome and its

583 components.

584 GLP-1RAs = glucagon-like peptide-1 receptor agonists. MACE = major adverse

585 cardiovascular events.

586

587 **Figure 2.** Effects of GLP-1 RAs on all-cause mortality, hospitalization due to heart

588 failure, and renal outcomes.

589 GLP-1RAs = glucagon-like peptide-1 receptor agonists.

590

591 **Figure 3.** Univariable meta-regression analysis of normalized reduction in HbA1c (A)
592 or body weight (B) with the logarithm of hazard ratio (log-HR) for the primary
593 composite MACE outcome.

594 The size of each trial's circle is inversely proportional to the variance of hazard ratio.

595 MACE = major adverse cardiovascular events.

596

597 **Figure 4.** Univariable meta-regression analysis of normalized reduction in HbA1c
598 reduction (A–D) or body weight (E–H) with the logarithm of hazard ratio (log-HR) for
599 all-cause mortality (A, E), nonfatal myocardial infarction (B, F), nonfatal stroke (C, G),
600 and composite renal outcome (D, H).

601 The size of each trial's circle is inversely proportional to the variance of hazard ratio.

602 Table 1.

Trial name	ELIXA	LEADER	SUSTAIN-6	EXSCEL	Harmony Outcomes	REWIND	PIONEER 6	AMPLITUDE-O
GLP-1 receptor agonists	Lixisenatide	Liraglutide	Semaglutide	Exenatide QW	Albiglutide	Dulaglutide	Oral semaglutide	Efpeglenatide
dose	20 µg/day	1.8 mg/day	0.5 or 1 mg/week	2 mg/week	30 or 50 mg/week	1.5 mg/week	14 mg/day	4 or 6 mg/week
Median year of follow-up (years)	2.1	3.8	2.1	3.2	1.5	5.4	1.3	1.8
Patients	6068	9340	3297	14752	9463	9901	3138	4076
Age	59.9 ± 9.7	64.2 ± 7.2	64.6 ± 7.4	62.0 (56.0-68.0)	64.1 ± 8.7	66.2 ± 6.5	66.0 ± 7.0	64.5 ± 8.2
Sex (%female)	1861 (31%)	3337 (36%)	1295 (39%)	5603 (38%)	2894 (31%)	4589 (46%)	1007 (32%)	1344 (33%)
Body mass index (kg/m2)	30.1 ± 5.6	32.5 ± 6.3	32.8 ± 6.2	31.8 (28.2-36.2)	32.3 ± 5.9	32.3 ± 5.7	32.3 ± 6.5	32.7 ± 6.2
White ethnicity	4576 (75%)	7238 (78%)	2736 (83%)	11175 (76%)	6583 (70%)	7498 (76%)	2300 (72%)	3534 (87%)
Duration of diabetes (years)	9.2 ± 8.2	12.8 ± 8.0	13.9 ± 8.1	12.0 (7.0-18.0)	14.1 ± 8.7	10.5 ± 7.2	14.9 ± 8.5	15.4 ± 8.8
HbA1c (%)	7.7 ± 1.3	8.7 ± 1.6	8.7 ± 1.5	8.0 (7.3-8.9)	8.7 ± 1.5	7.3 ± 1.1	8.2 ± 1.6	8.9 ± 1.5
Systolic blood pressure (mmHg)	129 ± 17	136 ± 18	136 ± 17	135 (124-145)	135 ± 17	137 ± 17	136 ± 18	135 ± 16
eGFR (mL/min/1.73 m2) †	78 ± 21	80	80 (61-92)	77 (61-92)	79 ± 25	75 (61-91)	74 ± 21	72 ± 22
Previous cardiovascular disease (%)	6068 (100%)	7598 (81%)	2735 (83%)	10782 (73%)	9463 (100%)	3114 (31%)	2695 (85%)	3650 (90%)
Previous heart failure (%)	1358 (22%)	1667 (18%)	777 (24%)	2389 (16%)	1922 (20%)	853 (9%)	288 (12%)	737 (18%)
Other glucose-lowering therapies								
Insulin	2374 (39%)	4169 (45%)	1913 (58%)	6368 (46%)	5597 (59%)	2363 (24%)	1930 (61%)	2560 (63%)
Metformin	4021 (66%)	7144 (76%)	2414 (73%)	11295 (77%)	6969 (74%)	8037 (81%)	2463 (77%)	2985 (72%)
Sulfonylurea	2004 (33%)	4733 (51%)	1410 (43%)	5401 (37%)	2725 (29%)	4552 (46%)	1027 (77%)	1036 (25%)
Thiazolidinedione	95 (2%)	575 (6%)	76 (2%)	579 (4%)	194 (2%)	168 (2%)	118 (4%)	–
DPP4 inhibitor	–	6 (<1%)	5 (<1%)	2203 (15%)	1437 (15%)	564 (6%)	2 (<1%)	–
SGLT2 inhibitor	–	–	5 (<1%)	77 (1%)	575 (6%)	620 (6%)	305 (10%)	618 (15%)

603 Continuous variables are presented as mean $\pm$ standard deviation (except for EXSCEL), and
 604 categorical variables are presented as numbers (%). Continuous data on EXSCEL are presented as
 605 median (Interquartile range, IQR).
 606 *eGFR data on SUSTAIN-6, EXSCEL, and REWIND are expressed as median (IQR). The standard
 607 deviation of eGFR in LEADER is not available.
 608 GLP-1 = glucagon-like peptide-1, Exenatide QW = Exenatide once weekly, HbA1c = glycated
 609 haemoglobin, eGFR = estimated glomerular filtration rate.
 610

Figure 1.

Figure 2.

Figure 3.

Figure 4.